Financings

Argos Therapeutics Inc. filed to raise up to $86.25 million in an initial public offering.

Fibrocell Science Inc. is raising $22.7 million through a private placement.

NuPathe Inc. entered a $30 million common stock purchase agreement with Aspire Capital Fund LLC.

Somaxon Pharmaceuticals Inc. established a $15 million term loan and $30 million at-the-market (ATM) offering agreement.

Deals

Acceleron Pharma Inc. licensed ACE-536 to Celgene Corp. for $25 million up front and $217 million in milestones.

AMAG Pharmaceuticals Inc. received a $378 million buyout offer from hedge fund MSMB Capital Management.

NPS Pharmaceuticals Inc. and GlaxoSmithKline plc ended their deal for calcilytic compounds, but expanded work on ronacaleret.

Vectura Group plc got $10 million up front in a deal with an undisclosed partner for VR315.

. . . And More

Active Biotech AB and Teva Pharmaceutical Industries Ltd.'s multiple sclerosis drug laquinimod failed Phase III.

Biotica Technology Ltd. regained rights to its rapamycin analogue program from Pfizer Inc.

Dendreon Corp. plummeted 67 percent and dragged down all of biotech with slow Provenge sales.

Insmed Inc.'s Phase III Arikace (liposomal amikacin) trials were put on clinical hold.

Rare Disease Therapeutics Inc. won FDA approval of scorpion sting antidote Anascorp.